{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T01:00:59Z","timestamp":1794877259306,"version":"4.9.1"},"reference-count":199,"publisher":"European Respiratory Society (ERS)","issue":"3","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/publications.ersnet.org\/user-licence"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2026,4,29]]},"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:p>Fibrosing interstitial lung disease encompasses a large number of diverse conditions, the prototype being idiopathic pulmonary fibrosis (IPF). IPF is characterised by irreversible progression and accounts for loss of lung function, exercise intolerance and complications, especially acute exacerbation and respiratory failure leading to early mortality. A significant proportion of patients with fibrosing interstitial lung diseases other than IPF will develop a progressive phenotype comparable to IPF. Progression occurs despite conventional treatment, which, depending on the underlying condition, may include close monitoring, antigen eviction, glucocorticoids, immunosuppressive therapy and pulmonary rehabilitation. Progressive pulmonary fibrosis (PPF) has a disease course similar to IPF, with worsening respiratory symptoms, decline in lung function, impairment of quality of life and premature death. In 2019, a phase 3 trial demonstrated that treatment with the tyrosine kinase inhibitor nintedanib halves disease progression as measured by a decline in forced vital capacity over 1 year, and contributed to the validation of the PPF concept. In the 2022 international clinical practice guideline, nintedanib received a conditional recommendation for treating patients with PPF. In 2025, it was demonstrated that the phosphodiesterase 4B inhibitor nerandomilast further reduces disease progression in patients with PPF. Other smaller trials have suggested that pirfenidone may also benefit patients with PPF. Several newer compounds are currently being developed for both IPF and PPF. Because a diagnosis of PPF identifies patients with fibrotic disease progression, early identification is warranted for the timely initiation of antifibrotic therapy, consideration of lung transplantation if eligible, and holistic care.<\/jats:p>","DOI":"10.1183\/13993003.01557-2025","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T16:05:20Z","timestamp":1781193920000},"page":"2501557","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Progressive pulmonary fibrosis: a state-of-the-art review"],"prefix":"10.1183","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5591-0955","authenticated-orcid":false,"given":"Vincent","family":"Cottin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7686-0291","authenticated-orcid":false,"given":"Kevin R.","family":"Flaherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3837-1467","authenticated-orcid":false,"given":"Martin","family":"Kolb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6329-2325","authenticated-orcid":false,"given":"David A.","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4957-8869","authenticated-orcid":false,"given":"Justin","family":"Oldham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0856-6290","authenticated-orcid":false,"given":"Claudia","family":"Valenzuela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4527-6962","authenticated-orcid":false,"given":"Marlies","family":"Wijsenbeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athol U.","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"2026100511101177000_68.3.2501557.1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00158-2025"},{"key":"2026100511101177000_68.3.2501557.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2005230"},{"key":"2026100511101177000_68.3.2501557.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1705751"},{"key":"2026100511101177000_68.3.2501557.4","doi-asserted-by":"crossref","unstructured":"Wells AU . Approach to diagnosis of diffuse lung disease . In: Albert RK , Spiro SG , Jett JR , eds. Clinical Respiratory Medicine. Philadelphia, Mosby\/Elsevier, 2004; pp. 647\u2013656.","DOI":"10.1016\/B978-032304825-5.10049-2"},{"key":"2026100511101177000_68.3.2501557.5","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200210-1245OC"},{"key":"2026100511101177000_68.3.2501557.6","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200403-331OC"},{"key":"2026100511101177000_68.3.2501557.7","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00692-2018"},{"key":"2026100511101177000_68.3.2501557.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908681"},{"key":"2026100511101177000_68.3.2501557.9","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0100-2018"},{"key":"2026100511101177000_68.3.2501557.10","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202202-0399ST"},{"key":"2026100511101177000_68.3.2501557.11","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1164\/rccm.202505-1142SO","article-title":"Standardized clinical terms and definitions for interstitial lung disease: a consensus statement from the Fleischner Society","volume":"211","author":"Ryerson","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"2026100511101177000_68.3.2501557.12","doi-asserted-by":"crossref","first-page":"799912","DOI":"10.3389\/fmed.2022.799912","article-title":"The burden of progressive-fibrosing interstitial lung diseases","volume":"9","author":"Cottin","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"2026100511101177000_68.3.2501557.13","doi-asserted-by":"crossref","first-page":"751181","DOI":"10.3389\/fmed.2021.751181","article-title":"Variability in global prevalence of interstitial lung disease","volume":"8","author":"Kaul","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2026100511101177000_68.3.2501557.14","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S2213-2600(25)00129-8","article-title":"Global epidemiology and burden of interstitial lung disease","volume":"13","author":"Spagnolo","year":"2025","journal-title":"Lancet Respir Med"},{"key":"2026100511101177000_68.3.2501557.15","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00597-2021"},{"key":"2026100511101177000_68.3.2501557.16","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1007\/s12325-020-01578-6","article-title":"Estimation of the prevalence of progressive fibrosing interstitial lung diseases: systematic literature review and data from a physician survey","volume":"38","author":"Olson","year":"2021","journal-title":"Adv Ther"},{"key":"2026100511101177000_68.3.2501557.17","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1513\/AnnalsATS.202102-222OC","article-title":"Claims-based prevalence of disease progression among patients with fibrosing interstitial lung disease other than idiopathic pulmonary fibrosis in the United States","volume":"19","author":"Singer","year":"2022","journal-title":"Ann Am Thorac Soc"},{"key":"2026100511101177000_68.3.2501557.18","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202201-0124OC"},{"key":"2026100511101177000_68.3.2501557.19","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1159\/000509556","article-title":"Progressive fibrosing interstitial lung diseases: prevalence and characterization in two Italian referral centers","volume":"99","author":"Faverio","year":"2020","journal-title":"Respiration"},{"key":"2026100511101177000_68.3.2501557.20","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1111\/resp.13942","article-title":"The unmet care needs of progressive fibrosing interstitial lung disease","volume":"25","author":"Sweeney","year":"2020","journal-title":"Respirology"},{"key":"2026100511101177000_68.3.2501557.21","doi-asserted-by":"crossref","first-page":"754851","DOI":"10.3389\/fphar.2021.754851","article-title":"Predictors of mortality in progressive fibrosing interstitial lung diseases","volume":"12","author":"Chen","year":"2021","journal-title":"Front Pharmacol"},{"key":"2026100511101177000_68.3.2501557.22","doi-asserted-by":"crossref","first-page":"e25322","DOI":"10.1097\/MD.0000000000025322","article-title":"Clinical characteristics of non-idiopathic pulmonary fibrosis, progressive fibrosing interstitial lung diseases: a single-center retrospective study","volume":"100","author":"Komatsu","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"2026100511101177000_68.3.2501557.23","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-021-01879-6"},{"key":"2026100511101177000_68.3.2501557.24","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02718-2020"},{"key":"2026100511101177000_68.3.2501557.25","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00221-2021"},{"key":"2026100511101177000_68.3.2501557.26","doi-asserted-by":"crossref","first-page":"23988","DOI":"10.1038\/s41598-021-03481-8","article-title":"Real-life prevalence of progressive fibrosing interstitial lung diseases","volume":"11","author":"Gagliardi","year":"2021","journal-title":"Sci Rep"},{"key":"2026100511101177000_68.3.2501557.27","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02571-2021"},{"key":"2026100511101177000_68.3.2501557.28","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/resp.14245","article-title":"Prevalence and prognosis of chronic fibrosing interstitial lung diseases with a progressive phenotype","volume":"27","author":"Takei","year":"2022","journal-title":"Respirology"},{"key":"2026100511101177000_68.3.2501557.29","doi-asserted-by":"crossref","first-page":"790204","DOI":"10.3389\/fphar.2021.790204","article-title":"Outcomes and incidence of PF-ILD according to different definitions in a real-world setting","volume":"12","author":"Torrisi","year":"2021","journal-title":"Front Pharmacol"},{"key":"2026100511101177000_68.3.2501557.30","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1097\/MCP.0000000000000908","article-title":"Epidemiology and real-life experience in progressive pulmonary fibrosis","volume":"28","author":"Valenzuela","year":"2022","journal-title":"Curr Opin Pulm Med"},{"key":"2026100511101177000_68.3.2501557.31","doi-asserted-by":"crossref","first-page":"1335758","DOI":"10.3389\/fmed.2024.1335758","article-title":"Risk factors for progression of pulmonary fibrosis: a single-centered, retrospective study","volume":"11","author":"Fan","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"2026100511101177000_68.3.2501557.32","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01396-2021"},{"key":"2026100511101177000_68.3.2501557.33","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.resinv.2024.05.005","article-title":"Progressive pulmonary fibrosis (PPF): estimation of incidence and treatment rates in Japan using a claims database","volume":"62","author":"Kondoh","year":"2024","journal-title":"Respir Investig"},{"key":"2026100511101177000_68.3.2501557.34","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1080\/03007995.2019.1647040","article-title":"Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management","volume":"35","author":"Wijsenbeek","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"2026100511101177000_68.3.2501557.35","doi-asserted-by":"publisher","DOI":"10.1378\/chest.13-0844"},{"key":"2026100511101177000_68.3.2501557.36","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02151-2019"},{"key":"2026100511101177000_68.3.2501557.37","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-021-01749-1"},{"key":"2026100511101177000_68.3.2501557.38","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0076-2018"},{"key":"2026100511101177000_68.3.2501557.39","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S2213-2600(20)30355-6","article-title":"Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities","volume":"8","author":"George","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2026100511101177000_68.3.2501557.40","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S2213-2600(19)30341-8","article-title":"Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"8","author":"Maher","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2026100511101177000_68.3.2501557.41","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S2213-2600(20)30554-3","article-title":"Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial","volume":"9","author":"Behr","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2026100511101177000_68.3.2501557.42","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.chest.2024.12.006","article-title":"COUNTERPOINT: should the progressive pulmonary fibrosis clinical practice guideline be adopted for clinical practice? No","volume":"167","author":"Oldham","year":"2025","journal-title":"Chest"},{"key":"2026100511101177000_68.3.2501557.43","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.chest.2024.12.007","article-title":"Rebuttal from Drs Oldham and Cottin","volume":"167","author":"Oldham","year":"2025","journal-title":"Chest"},{"key":"2026100511101177000_68.3.2501557.44","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1164\/rccm.202206-1166LE","article-title":"Progressive pulmonary fibrosis: putting the cart before the horse","volume":"206","author":"Johannson","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026100511101177000_68.3.2501557.45","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1164\/rccm.202206-1143LE","article-title":"Progressive pulmonary fibrosis: should the timelines be taken out of the definition?","volume":"206","author":"Cottin","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026100511101177000_68.3.2501557.46","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1164\/rccm.202208-1639ED","article-title":"Criteria for progressive pulmonary fibrosis: getting the horse ready for the cart","volume":"207","author":"Cottin","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"2026100511101177000_68.3.2501557.47","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.161.2.ats3-00"},{"key":"2026100511101177000_68.3.2501557.48","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202306-1113ST"},{"key":"2026100511101177000_68.3.2501557.49","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.04587-2020"},{"key":"2026100511101177000_68.3.2501557.50","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2021.04.037"},{"key":"2026100511101177000_68.3.2501557.51","doi-asserted-by":"publisher","DOI":"10.1164\/RCCM.202205-0910LE"},{"key":"2026100511101177000_68.3.2501557.52","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-024-03070-z"},{"key":"2026100511101177000_68.3.2501557.53","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1164\/rccm.202501-0317OC","article-title":"Performance characteristics for physiological measures of progressive pulmonary fibrosis","volume":"211","author":"Newton","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"2026100511101177000_68.3.2501557.54","doi-asserted-by":"publisher","DOI":"10.1148\/radiology.189.3.8080483"},{"key":"2026100511101177000_68.3.2501557.55","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.rmed.2018.07.014","article-title":"Evolution of diagnostic UIP computed tomography patterns in idiopathic pulmonary fibrosis: disease spectrum and implications for survival","volume":"142","author":"De Giacomi","year":"2018","journal-title":"Respir Med"},{"key":"2026100511101177000_68.3.2501557.56","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.clinimag.2019.07.003","article-title":"Progression of probable UIP and UIP on HRCT","volume":"58","author":"Salvatore","year":"2019","journal-title":"Clin Imaging"},{"key":"2026100511101177000_68.3.2501557.57","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2019-213865"},{"key":"2026100511101177000_68.3.2501557.58","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1007\/s00330-019-06402-6","article-title":"Prediction of idiopathic pulmonary fibrosis progression using early quantitative changes on CT imaging for a short term of clinical 18\u201324-month follow-ups","volume":"30","author":"Kim","year":"2020","journal-title":"Eur Radiol"},{"key":"2026100511101177000_68.3.2501557.59","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejrad.2012.02.014","article-title":"CT analysis of the effect of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"83","author":"Iwasawa","year":"2014","journal-title":"Eur J Radiol"},{"key":"2026100511101177000_68.3.2501557.60","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01384-2018"},{"key":"2026100511101177000_68.3.2501557.61","doi-asserted-by":"publisher","DOI":"10.1016\/j.crad.2004.06.029"},{"key":"2026100511101177000_68.3.2501557.62","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1097\/RCT.0b013e31822a5883","article-title":"Nonspecific interstitial pneumonia: prognostic significance of high-resolution computed tomography in 59 patients","volume":"35","author":"Hozumi","year":"2011","journal-title":"J Comput Assist Tomogr"},{"key":"2026100511101177000_68.3.2501557.63","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2471070369"},{"key":"2026100511101177000_68.3.2501557.64","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2010.140574"},{"key":"2026100511101177000_68.3.2501557.65","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.173.4.10511155"},{"key":"2026100511101177000_68.3.2501557.66","doi-asserted-by":"publisher","DOI":"10.1097\/RCT.0b013e31823ed437"},{"key":"2026100511101177000_68.3.2501557.67","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e3182387d0c"},{"key":"2026100511101177000_68.3.2501557.68","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-020-07469-2"},{"key":"2026100511101177000_68.3.2501557.69","doi-asserted-by":"publisher","DOI":"10.1097\/RCT.0b013e318209c5a6"},{"key":"2026100511101177000_68.3.2501557.70","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.rmed.2018.03.031","article-title":"Functional associations of pleuroparenchymal fibroelastosis and emphysema with hypersensitivity pneumonitis","volume":"138","author":"Jacob","year":"2018","journal-title":"Respir Med"},{"key":"2026100511101177000_68.3.2501557.71","doi-asserted-by":"publisher","DOI":"10.1148\/radiology.189.1.8372179"},{"key":"2026100511101177000_68.3.2501557.72","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-003-1848-1"},{"key":"2026100511101177000_68.3.2501557.73","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3003.2000.16a10.x"},{"key":"2026100511101177000_68.3.2501557.74","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.03187-2021"},{"key":"2026100511101177000_68.3.2501557.75","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1513\/AnnalsATS.201906-437OC","article-title":"Associations between patient-reported outcomes and death or lung transplant in idiopathic pulmonary fibrosis. Data from the idiopathic pulmonary fibrosis prospective outcomes registry","volume":"17","author":"Case","year":"2020","journal-title":"Ann Am Thorac Soc"},{"key":"2026100511101177000_68.3.2501557.76","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2022.03.025"},{"key":"2026100511101177000_68.3.2501557.77","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.3390\/jcm12113787","article-title":"Clinical impact of physical activity and cough on disease progression in fibrotic interstitial lung disease","volume":"12","author":"Veit","year":"2023","journal-title":"J Clin Med"},{"key":"2026100511101177000_68.3.2501557.78","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02211-2023"},{"key":"2026100511101177000_68.3.2501557.79","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202311-2169LE"},{"key":"2026100511101177000_68.3.2501557.80","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00145-2020"},{"key":"2026100511101177000_68.3.2501557.81","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2021-001167"},{"key":"2026100511101177000_68.3.2501557.82","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01531-2021"},{"key":"2026100511101177000_68.3.2501557.83","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1513\/AnnalsATS.202307-658OC","article-title":"Validation of a dyspnea visual analog scale in fibrotic interstitial lung disease","volume":"21","author":"Bevanda","year":"2024","journal-title":"Ann Am Thorac Soc"},{"key":"2026100511101177000_68.3.2501557.84","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00917-2021"},{"key":"2026100511101177000_68.3.2501557.85","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2023-220541"},{"key":"2026100511101177000_68.3.2501557.86","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S2213-2600(21)00503-8","article-title":"Proteomic biomarkers of progressive fibrosing interstitial lung disease: a multicentre cohort analysis","volume":"10","author":"Bowman","year":"2022","journal-title":"Lancet Respir Med"},{"key":"2026100511101177000_68.3.2501557.87","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1164\/rccm.202407-1506OC","article-title":"Proteomic biomarkers of survival in non-idiopathic pulmonary fibrosis interstitial lung disease","volume":"211","author":"Alqalyoobi","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"2026100511101177000_68.3.2501557.88","doi-asserted-by":"crossref","first-page":"e241001","DOI":"10.1148\/radiol.241001","article-title":"CT honeycombing and traction bronchiectasis extent independently predict survival across fibrotic interstitial lung disease subtypes","volume":"314","author":"Marinescu","year":"2025","journal-title":"Radiology"},{"key":"2026100511101177000_68.3.2501557.89","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1164\/rccm.202501-0208OC","article-title":"A quantitative imaging measure of progressive pulmonary fibrosis","volume":"211","author":"Wang","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"2026100511101177000_68.3.2501557.90","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1164\/rccm.202503-0535OC","article-title":"One-year change in quantitative computed tomography is associated with meaningful outcomes in fibrotic lung disease","volume":"211","author":"Koslow","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"2026100511101177000_68.3.2501557.91","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0003-2022"},{"key":"2026100511101177000_68.3.2501557.92","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055120"},{"key":"2026100511101177000_68.3.2501557.93","doi-asserted-by":"publisher","DOI":"10.1002\/art.22204"},{"key":"2026100511101177000_68.3.2501557.94","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200702-326OC"},{"key":"2026100511101177000_68.3.2501557.95","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2026100511101177000_68.3.2501557.96","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.201802-079OC"},{"key":"2026100511101177000_68.3.2501557.97","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/acr.23282","article-title":"Efficacy of mycophenolate mofetil and oral cyclophosphamide on skin thickness: post hoc analyses from two randomized placebo-controlled trials","volume":"70","author":"Namas","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026100511101177000_68.3.2501557.98","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2016.11.052"},{"key":"2026100511101177000_68.3.2501557.99","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/acr2.11125","article-title":"Treatment with mycophenolate and cyclophosphamide leads to clinically meaningful improvements in patient-reported outcomes in scleroderma lung disease: results of Scleroderma Lung Study II","volume":"2","author":"Volkmann","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"2026100511101177000_68.3.2501557.100","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/art.40114","article-title":"Mycophenolate mofetil versus placebo for systemic sclerosis-related interstitial lung disease: an analysis of Scleroderma Lung Studies I and II","volume":"69","author":"Volkmann","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2026100511101177000_68.3.2501557.101","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1055\/s-0044-1786698","article-title":"Interstitial lung disease associated with systemic sclerosis","volume":"45","author":"Mismetti","year":"2024","journal-title":"Semin Respir Crit Care Med"},{"key":"2026100511101177000_68.3.2501557.102","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00296-019-04481-8","article-title":"Effect of mycophenolate mofetil (MMF) on systemic sclerosis-related interstitial lung disease with mildly impaired lung function: a double-blind, placebo-controlled, randomized trial","volume":"40","author":"Naidu","year":"2020","journal-title":"Rheumatol Int"},{"key":"2026100511101177000_68.3.2501557.103","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S2213-2600(20)30330-1","article-title":"Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial","volume":"9","author":"Highland","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2026100511101177000_68.3.2501557.104","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00232-4"},{"key":"2026100511101177000_68.3.2501557.105","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2026100511101177000_68.3.2501557.106","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202103-0714OC"},{"key":"2026100511101177000_68.3.2501557.107","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211682"},{"key":"2026100511101177000_68.3.2501557.108","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.1016\/S2665-9913(21)00107-7","article-title":"Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial","volume":"3","author":"Ebata","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"2026100511101177000_68.3.2501557.109","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key213"},{"key":"2026100511101177000_68.3.2501557.110","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2016-000384"},{"key":"2026100511101177000_68.3.2501557.111","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.autrev.2018.07.013","article-title":"Treatment of idiopathic inflammatory myositis associated interstitial lung disease: a systematic review and meta-analysis","volume":"18","author":"Barba","year":"2019","journal-title":"Autoimmun Rev"},{"key":"2026100511101177000_68.3.2501557.112","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","article-title":"Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial","volume":"11","author":"Maher","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2026100511101177000_68.3.2501557.113","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02071-2022"},{"key":"2026100511101177000_68.3.2501557.114","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00150-2015"},{"key":"2026100511101177000_68.3.2501557.115","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2022.11.035"},{"key":"2026100511101177000_68.3.2501557.116","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2023-002163"},{"key":"2026100511101177000_68.3.2501557.117","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2016.10.029"},{"key":"2026100511101177000_68.3.2501557.118","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3390\/jcm8010014","article-title":"Effects of corticosteroid treatment and antigen avoidance in a large hypersensitivity pneumonitis cohort: a single-centre cohort study","volume":"8","author":"De Sadeleer","year":"2018","journal-title":"J Clin Med"},{"key":"2026100511101177000_68.3.2501557.119","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/s12890-021-01608-1","article-title":"Efficacy of treatment with corticosteroids for fibrotic hypersensitivity pneumonitis: a propensity score-matched cohort analysis","volume":"21","author":"Ejima","year":"2021","journal-title":"BMC Pulm Med"},{"key":"2026100511101177000_68.3.2501557.120","doi-asserted-by":"crossref","first-page":"19011983","DOI":"10.1183\/13993003.01983-2019","article-title":"Impact of BAL lymphocytosis and presence of honeycombing on corticosteroid treatment effect in fibrotic hypersensitivity pneumonitis: a retrospective cohort study","volume":"55","author":"De Sadeleer","year":"2020","journal-title":"Eur Respir J"},{"key":"2026100511101177000_68.3.2501557.121","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/j.chest.2023.12.019","article-title":"Impact of antigen exposure on outcomes and treatment response in fibrotic hypersensitivity pneumonitis","volume":"165","author":"Mullin","year":"2024","journal-title":"Chest"},{"key":"2026100511101177000_68.3.2501557.122","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00441-2023"},{"key":"2026100511101177000_68.3.2501557.123","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02872-2020"},{"key":"2026100511101177000_68.3.2501557.124","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-015-0835-7"},{"key":"2026100511101177000_68.3.2501557.125","doi-asserted-by":"crossref","first-page":"e233640","DOI":"10.1001\/jamanetworkopen.2023.3640","article-title":"Incidence of interstitial lung disease in patients with rheumatoid arthritis treated with biologic and targeted synthetic disease-modifying antirheumatic drugs","volume":"6","author":"Baker","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2026100511101177000_68.3.2501557.126","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s41927-024-00374-x","article-title":"Janus kinase inhibitors vs. abatacept about safety and efficacy for patients with rheumatoid arthritis-associated interstitial lung disease: a retrospective nested case-control study","volume":"8","author":"Tsujii","year":"2024","journal-title":"BMC Rheumatol"},{"key":"2026100511101177000_68.3.2501557.127","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/resp.14409","article-title":"Immunomodulatory treatment in unclassifiable interstitial lung disease: a retrospective study of treatment response","volume":"28","author":"Hyldgaard","year":"2023","journal-title":"Respirology"},{"key":"2026100511101177000_68.3.2501557.128","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1300575"},{"key":"2026100511101177000_68.3.2501557.129","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2938-9"},{"key":"2026100511101177000_68.3.2501557.130","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aba1983"},{"key":"2026100511101177000_68.3.2501557.131","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-63735-1"},{"key":"2026100511101177000_68.3.2501557.132","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00239.2023"},{"key":"2026100511101177000_68.3.2501557.133","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1165\/rcmb.2024-0255OC","article-title":"Targeting the epigenetic regulator CBX5 promotes fibroblast metabolic reprogramming and inhibits lung fibrosis","volume":"72","author":"Hong","year":"2025","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2026100511101177000_68.3.2501557.134","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/s41467-026-68354-y","article-title":"Transcriptomic signature-guided depletion of intermediate alveolar epithelial cells ameliorates pulmonary fibrosis in mice","volume":"17","author":"Peng","year":"2026","journal-title":"Nat Commun"},{"key":"2026100511101177000_68.3.2501557.135","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1165\/rcmb.2025-0137TR","article-title":"Pulmonary fibrosis \u2013 focusing on the future: Aspen lung conference 2024 summary","volume":"73","author":"Freeberg","year":"2025","journal-title":"Am J Respir Cell Mol Biol"},{"key":"2026100511101177000_68.3.2501557.136","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/iid3.377","article-title":"Animal models of rheumatoid arthritis-associated interstitial lung disease","volume":"9","author":"Xiong","year":"2021","journal-title":"Immun Inflamm Dis"},{"key":"2026100511101177000_68.3.2501557.137","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000967"},{"key":"2026100511101177000_68.3.2501557.138","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0127-2023"},{"key":"2026100511101177000_68.3.2501557.139","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/MCP.0000000000000803","article-title":"The justification for the progressive fibrotic phenotype","volume":"27","author":"Kolb","year":"2021","journal-title":"Curr Opin Pulm Med"},{"key":"2026100511101177000_68.3.2501557.140","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801562"},{"key":"2026100511101177000_68.3.2501557.141","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201902-0360OC"},{"key":"2026100511101177000_68.3.2501557.142","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.chest.2018.12.011","article-title":"Integrating genomics into management of fibrotic interstitial lung disease","volume":"155","author":"Adegunsoye","year":"2019","journal-title":"Chest"},{"key":"2026100511101177000_68.3.2501557.143","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0189467"},{"key":"2026100511101177000_68.3.2501557.144","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00308-2016"},{"key":"2026100511101177000_68.3.2501557.145","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-019-0322-7"},{"key":"2026100511101177000_68.3.2501557.146","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00404-2023"},{"key":"2026100511101177000_68.3.2501557.147","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00174914"},{"key":"2026100511101177000_68.3.2501557.148","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00161-2019"},{"key":"2026100511101177000_68.3.2501557.149","doi-asserted-by":"crossref","first-page":"102267","DOI":"10.1016\/j.pupt.2023.102267","article-title":"Anti-fibrotic effects of nintedanib on lung fibroblasts derived from patients with progressive fibrosing interstitial lung diseases (PF-ILDs)","volume":"83","author":"Joannes","year":"2023","journal-title":"Pulm Pharmacol Ther"},{"key":"2026100511101177000_68.3.2501557.150","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103690"},{"key":"2026100511101177000_68.3.2501557.151","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402584"},{"key":"2026100511101177000_68.3.2501557.152","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2016.02.001"},{"key":"2026100511101177000_68.3.2501557.153","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903076"},{"key":"2026100511101177000_68.3.2501557.154","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/art.41576","article-title":"Effect of nintedanib on lung function in patients with systemic sclerosis-associated interstitial lung disease: further analyses of a randomized, double-blind, placebo-controlled trial","volume":"73","author":"Maher","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2026100511101177000_68.3.2501557.155","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2021.06.049"},{"key":"2026100511101177000_68.3.2501557.156","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.04538-2020"},{"key":"2026100511101177000_68.3.2501557.157","doi-asserted-by":"crossref","first-page":"5536","DOI":"10.1007\/s12325-023-02668-x","article-title":"Effect of nintedanib in patients with progressive pulmonary fibrosis in subgroups with differing baseline characteristics","volume":"40","author":"Kolb","year":"2023","journal-title":"Adv Ther"},{"key":"2026100511101177000_68.3.2501557.158","doi-asserted-by":"crossref","first-page":"e679","DOI":"10.1016\/S2665-9913(22)00215-6","article-title":"Safety and tolerability of nintedanib in patients with interstitial lung diseases in subgroups by sex: a post hoc analysis of pooled data from four randomised controlled trials","volume":"4","author":"Hoffmann-Vold","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"2026100511101177000_68.3.2501557.159","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S2213-2600(20)30036-9","article-title":"Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial","volume":"8","author":"Wells","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2026100511101177000_68.3.2501557.160","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00752-2023"},{"key":"2026100511101177000_68.3.2501557.161","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12931-021-01668-1","article-title":"Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases","volume":"22","author":"Cottin","year":"2021","journal-title":"Respir Res"},{"key":"2026100511101177000_68.3.2501557.162","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00085-2020"},{"key":"2026100511101177000_68.3.2501557.163","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60405-4"},{"key":"2026100511101177000_68.3.2501557.164","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402582"},{"key":"2026100511101177000_68.3.2501557.165","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S2213-2600(16)30326-5","article-title":"Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis","volume":"5","author":"Nathan","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2026100511101177000_68.3.2501557.166","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S2213-2600(22)00260-0","article-title":"Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study","volume":"11","author":"Solomon","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2026100511101177000_68.3.2501557.167","doi-asserted-by":"publisher","DOI":"10.1136\/thorax-2022-219795"},{"key":"2026100511101177000_68.3.2501557.168","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2018-000289"},{"key":"2026100511101177000_68.3.2501557.169","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s12325-021-02009-w","article-title":"Pirfenidone in unclassifiable interstitial lung disease: a subgroup analysis by concomitant mycophenolate mofetil and\/or previous corticosteroid use","volume":"39","author":"Kreuter","year":"2022","journal-title":"Adv Ther"},{"key":"2026100511101177000_68.3.2501557.170","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3389\/fphar.2020.00259","article-title":"Inhaled phosphodiesterase 4 (PDE4) inhibitors for inflammatory respiratory diseases","volume":"11","author":"Phillips","year":"2020","journal-title":"Front Pharmacol"},{"key":"2026100511101177000_68.3.2501557.171","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2008.00041.x"},{"key":"2026100511101177000_68.3.2501557.172","doi-asserted-by":"crossref","first-page":"e13753","DOI":"10.14814\/phy2.13753","article-title":"Phosphodiesterase 4 inhibition reduces lung fibrosis following targeted type II alveolar epithelial cell injury","volume":"6","author":"Sisson","year":"2018","journal-title":"Physiol Rep"},{"key":"2026100511101177000_68.3.2501557.173","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.838449"},{"key":"2026100511101177000_68.3.2501557.174","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/S0165-6147(02)02089-8","article-title":"4D or not 4D \u2013 the emetogenic basis of PDE4 inhibitors uncovered?","volume":"23","author":"Giembycz","year":"2002","journal-title":"Trends Pharmacol Sci"},{"key":"2026100511101177000_68.3.2501557.175","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2022-001580"},{"key":"2026100511101177000_68.3.2501557.176","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12890-025-03973-7","article-title":"Design of an open-label extension trial of nerandomilast (BI 1015550) in patients with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis (FIBRONEER-ON)","volume":"26","author":"Wuyts","year":"2025","journal-title":"BMC Pulm Med"},{"key":"2026100511101177000_68.3.2501557.177","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2503643"},{"key":"2026100511101177000_68.3.2501557.178","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01899-2025"},{"key":"2026100511101177000_68.3.2501557.179","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/14728214.2024.2340723","article-title":"Treatment of idiopathic pulmonary fibrosis: an update on emerging drugs in phase II & III clinical trials","volume":"29","author":"MacIsaac","year":"2024","journal-title":"Expert Opin Emerg Drugs"},{"key":"2026100511101177000_68.3.2501557.180","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2021-001026"},{"key":"2026100511101177000_68.3.2501557.181","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1164\/rccm.202405-0977OC","article-title":"Efficacy and safety of admilparant, an LPA1 antagonist in pulmonary fibrosis: a phase 2 randomized clinical trial","volume":"211","author":"Corte","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"2026100511101177000_68.3.2501557.182","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.chest.2025.04.003","article-title":"Effect of admilparant, a lysophosphatidic acid receptor 1 antagonist, on disease progression in pulmonary fibrosis","volume":"168","author":"Kreutzer","year":"2025","journal-title":"Chest"},{"key":"2026100511101177000_68.3.2501557.183","doi-asserted-by":"crossref","first-page":"100124","DOI":"10.1016\/j.chpulm.2024.100124","article-title":"Study design and rationale for the TETON-PPF phase 3, randomized, controlled clinical trial of inhaled treprostinil in the treatment of progressive pulmonary fibrosis","volume":"3","author":"Nathan","year":"2025","journal-title":"Chest Pulm"},{"key":"2026100511101177000_68.3.2501557.184","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2024-003059"},{"key":"2026100511101177000_68.3.2501557.185","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0265-2025"},{"key":"2026100511101177000_68.3.2501557.186","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJMoa2512911","article-title":"Inhaled treprostinil for idiopathic pulmonary fibrosis","volume":"395","author":"Nathan","year":"2026","journal-title":"N Engl J Med"},{"key":"2026100511101177000_68.3.2501557.187","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1513\/AnnalsATS.202103-343OC","article-title":"Nintedanib in progressive pulmonary fibrosis: a systematic review and meta-analysis","volume":"19","author":"Ghazipura","year":"2022","journal-title":"Ann Am Thorac Soc"},{"key":"2026100511101177000_68.3.2501557.188","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1513\/AnnalsATS.202103-342OC","article-title":"Pirfenidone in progressive pulmonary fibrosis: a systematic review and meta-analysis","volume":"19","author":"Ghazipura","year":"2022","journal-title":"Ann Am Thorac Soc"},{"key":"2026100511101177000_68.3.2501557.189","first-page":"100948","article-title":"French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis \u2013 2021 update. Full-length version","volume":"83","author":"Cottin","year":"2023","journal-title":"Respir Med Res"},{"key":"2026100511101177000_68.3.2501557.190","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1055\/a-1983-6796","article-title":"Pharmakotherapie der idiopathischen Lungenfibrose (ein Update) und anderer progredienter pulmonaler Fibrosen \u2013 S2k-Leitline der Deutsche Gesellschaft f\u00fcr Pneumologie und Beatmungsmedizin e.\u200aV. [Pharmacological treatment of idiopathic pulmonary fibrosis (update) and progressive pulmonary fibrosis \u2013 S2k Guideline of the German Respiratory Society","volume":"77","author":"Behr","year":"2023","journal-title":"Pneumologie"},{"key":"2026100511101177000_68.3.2501557.191","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/resp.14656","article-title":"Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: a position statement from the Thoracic Society of Australia and New Zealand 2023 revision","volume":"29","author":"Mackintosh","year":"2024","journal-title":"Respirology"},{"key":"2026100511101177000_68.3.2501557.192","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/art.42861","article-title":"2023 American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic diseases","volume":"76","author":"Johnson","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"2026100511101177000_68.3.2501557.193","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01973-2025"},{"key":"2026100511101177000_68.3.2501557.194","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002667"},{"key":"2026100511101177000_68.3.2501557.195","doi-asserted-by":"crossref","first-page":"00423\u20132022","DOI":"10.1183\/23120541.00423-2022","article-title":"Nintedanib for non-IPF progressive pulmonary fibrosis: 12-month outcome data from a real-world multicentre observational study","volume":"9","author":"Raman","year":"2023","journal-title":"ERJ Open Res"},{"key":"2026100511101177000_68.3.2501557.196","doi-asserted-by":"crossref","first-page":"00529\u20132023","DOI":"10.1183\/23120541.00529-2023","article-title":"Real-world experience of nintedanib for progressive fibrosing interstitial lung disease in the UK","volume":"10","author":"Dixon","year":"2024","journal-title":"ERJ Open Res"},{"key":"2026100511101177000_68.3.2501557.197","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/resp.70030","article-title":"Lung function course of patients with pulmonary fibrosis after initiation of anti-fibrotic treatment: real-world data from the Dutch national registry","volume":"30","author":"Platenburg","year":"2025","journal-title":"Respirology"},{"key":"2026100511101177000_68.3.2501557.198","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12890-026-04120-6","article-title":"Nintedanib for progressive pulmonary fibrosis in real-world setting: an observational study comparing outcomes with an IPF cohort","volume":"26","author":"Muscato","year":"2026","journal-title":"BMC Pulm Med"},{"key":"2026100511101177000_68.3.2501557.199","doi-asserted-by":"crossref","first-page":"107603","DOI":"10.1016\/j.rmed.2024.107603","article-title":"Predictive factors for dose reduction and discontinuation of nintedanib in fibrotic interstitial lung diseases: real life data","volume":"225","author":"Costa","year":"2024","journal-title":"Respir Med"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.01557-2025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T18:10:29Z","timestamp":1791223829000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.01557-2025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":199,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,9,25]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1183\/13993003.01557-2025"],"URL":"https:\/\/doi.org\/10.1183\/13993003.01557-2025","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]}}}